2005   Dec, 20 Lupin Receives US FDA Approval For Cefprozil Suspension   Dec, 9 Lupin receives US FDA approval for Cefprozil Tablets   Dec, 7 Lupin Limited places US $ 100 million Foreign Currency Convertible Bonds   Dec, 1 Lupin receives USFDA approval for Cephalexin Capsules   Nov, 28 Lupin Receives Approval For Conducting Phase II Trials For LLL-3348 (Desoris)   Oct, 24 Lupin has entered into an agreement with GSK Philippines   Oct, 19 Lupin Q2FY06 Net Profit Soars 158% to Rs. 452 mn Dr. Vijay Kelkar and Mr. R A Shah join Lupin Board   Sept, 27 Lupin – Ranbaxy Sign TB deal   Sept, 26 Lupin and Aspen Sign TB Deal   Sept, 2 DSM Anti-Infectives India And Lupin Enter Into A Strategic Cooperation For Cephalosporins   Aug, 18 Lupin receives USFDA approval for Cephalexin Oral Suspension   Aug, 10 ICRA assigns A1+ rating to short term debt programme of Lupin   Aug, 8 Lupin enters into a co-operation agreement with Kyowa for Japanese market   Aug, 2 Lupin Q1 FY06 Net Profit doubles to Rs. 432 mn   July, 21 Lupin launches Ceftriaxone vials in the US market   July, 8 Lupin’s Goa Non Cephalosporin Oral Dosage Facility Inspected By USFDA   May, 20 Lupin FY 05 Net Sales up 4% at Rs. 11,611 mn   Jan, 27 Lupin Pharmaceuticals, Inc. and Cornerstone BioPharma, Inc.Enter Co-Promotion Agreement for Suprax®   Jan, 25 Lupin Net Sales up 10% at Rs. 2,796 mn